Tabula Rasa Healthcare (TRHC) Given Media Sentiment Score of 0.29

News headlines about Tabula Rasa Healthcare (NASDAQ:TRHC) have trended positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tabula Rasa Healthcare earned a media sentiment score of 0.29 on Accern’s scale. Accern also assigned headlines about the company an impact score of 44.652472886321 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the news headlines that may have effected Accern’s scoring:

Shares of Tabula Rasa Healthcare (TRHC) traded down 2.46% during midday trading on Wednesday, reaching $26.18. The company had a trading volume of 81,349 shares. The company has a 50 day moving average of $26.17 and a 200 day moving average of $26.17. Tabula Rasa Healthcare has a 12-month low of $10.39 and a 12-month high of $28.53. The firm’s market capitalization is $452.55 million.

Tabula Rasa Healthcare (NASDAQ:TRHC) last announced its earnings results on Monday, August 7th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.06. The business had revenue of $29.70 million for the quarter, compared to analysts’ expectations of $27.84 million. Tabula Rasa Healthcare had a negative return on equity of 9.58% and a negative net margin of 10.27%. Tabula Rasa Healthcare’s revenue was up 32.6% compared to the same quarter last year. Analysts anticipate that Tabula Rasa Healthcare will post $0.39 EPS for the current year.

TRHC has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Tabula Rasa Healthcare from a “hold” rating to a “strong-buy” rating and set a $31.00 target price on the stock in a research note on Wednesday, October 11th. Piper Jaffray Companies reiterated an “overweight” rating and set a $29.00 target price (up from $20.00) on shares of Tabula Rasa Healthcare in a research note on Wednesday, September 20th. Chardan Capital lifted their target price on Tabula Rasa Healthcare from $19.50 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Stifel Nicolaus reiterated a “buy” rating and set a $16.00 target price on shares of Tabula Rasa Healthcare in a research note on Friday, July 14th. Finally, ValuEngine upgraded Tabula Rasa Healthcare from a “sell” rating to a “hold” rating in a research note on Saturday, September 30th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $24.71.

ILLEGAL ACTIVITY WARNING: “Tabula Rasa Healthcare (TRHC) Given Media Sentiment Score of 0.29” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/2968928/tabula-rasa-healthcare-trhc-given-media-sentiment-score-of-0-29.html.

In other Tabula Rasa Healthcare news, CEO Calvin H. Knowlton sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The stock was sold at an average price of $17.21, for a total value of $137,680.00. Following the transaction, the chief executive officer now directly owns 918,362 shares of the company’s stock, valued at $15,805,010.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 45.80% of the company’s stock.

Tabula Rasa Healthcare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Insider Buying and Selling by Quarter for Tabula Rasa Healthcare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.